Kenneth Myszkowski - Arrowhead Pharmaceuticals Chief Officer
| HDP1 Stock | EUR 21.10 0.45 2.18% |
Executive
Mr. Kenneth Allen Myszkowski is the Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. Mr. Myszkowski joined Arrowhead in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two startup ventures NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided online tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen Co. in Chicago, Illinois since 2010.
| Age | 57 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Phone | 626 304 3400 |
| Web | https://arrowheadpharma.com |
Kenneth Myszkowski Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kenneth Myszkowski against Arrowhead Pharmaceuticals stock is an integral part of due diligence when investing in Arrowhead Pharmaceuticals. Kenneth Myszkowski insider activity provides valuable insight into whether Arrowhead Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Arrowhead Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Arrowhead Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kenneth Myszkowski over six months ago Disposition of 15000 shares by Kenneth Myszkowski of Arrowhead Pharmaceuticals at 36.2 subject to Rule 16b-3 |
Arrowhead Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1285) % which means that it has lost $0.1285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4043) %, meaning that it generated substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | EXECUTIVE Age | ||
| Vandad Fartaj | PennyMac Mortgage Investment | 48 | |
| Boon Pua | CDL INVESTMENT | N/A | |
| Daniel Perotti | PennyMac Mortgage Investment | 42 | |
| Douglas Jones | PennyMac Mortgage Investment | 66 | |
| Bryan Edmiston | WisdomTree Investments | 47 | |
| Jeffrey Grogin | PennyMac Mortgage Investment | 63 | |
| Jason Adams | CDL INVESTMENT | N/A | |
| Natasha Hood | CDL INVESTMENT | N/A | |
| Anne McCallion | PennyMac Mortgage Investment | 68 | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 |
Arrowhead Pharmaceuticals Leadership Team
Elected by the shareholders, the Arrowhead Pharmaceuticals' board of directors comprises two types of representatives: Arrowhead Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrowhead. The board's role is to monitor Arrowhead Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arrowhead Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrowhead Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tracie Oliver, Chief Officer | ||
| Kenneth Myszkowski, Chief Officer | ||
| Christopher Anzalone, President CEO, Director | ||
| Javier MD, Chief Officer | ||
| PharmD JD, COO Counsel | ||
| Howard Lovy, Director Communications | ||
| Vincent CFA, Head VP | ||
| Mark Davis, Founder Calando | ||
| MBA MD, VP Medicine | ||
| Mark Seefeld, Head VP |
Arrowhead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrowhead Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 108.31 M | |||
| Shares Owned By Insiders | 4.93 % | |||
| Shares Owned By Institutions | 69.27 % | |||
| Price To Earning | 263.63 X | |||
| Price To Book | 8.32 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Arrowhead Stock
When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.